Key takeaways
Prandimet (metformin/repaglinide) and miglitol (Glyset) are both used to control blood sugar in people with type 2 diabetes, but they work in different ways and have different availability statuses. Prandimet is a combination of two medications, metformin and repaglinide, which work together to lower blood sugar by increasing insulin production and reducing sugar production and absorption. However, Prandimet has been discontinued and is no longer available in the United States. Prandimet's individual components, metformin and repaglinide, are still available separately though. In contrast, miglitol is still available by prescription and works by slowing the breakdown of carbohydrates, which helps prevent high blood sugar after meals. Miglitol is taken three times daily with meals and is known for not causing weight gain or hypoglycemia when used alone. However, it can cause gastrointestinal side effects like gas and diarrhea. Unlike Prandimet, miglitol is not recommended for people with certain intestinal or kidney problems.
